Fibrose pulmonar idiopática (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Fibrose pulmonar idiopática" in Portuguese language version.

refsWebsite

Global rank Portuguese rank

69nih.gov

4^th place

8^th place

68doi.org

2^nd place

4^th place

5handle.net

102^nd place

459^th place

4worldcat.org

5^th place

4web.archive.org

1^st place

3semanticscholar.org

11^th place

968^th place

2atsjournals.org

low place

2psu.edu

207^th place

589^th place

2europa.eu

68^th place

56^th place

1books.google.com

3^rd place

6^th place

1biomedcentral.com

2,747^th place

1,815^th place

1omim.org

4,380^th place

low place

1uq.edu.au

3,558^th place

2,976^th place

1unisi.it

low place

1uva.nl

3,518^th place

3,782^nd place

1groovygecko.net

low place

1fda.gov

447^th place

869^th place

1harvard.edu

18^th place

51^st place

1bmj.com

1,226^th place

1,055^th place

1akcchf.org

low place

1coalitionforpf.org

low place

1pulmonaryfibrosisnews.com

low place

1sciencedaily.com

993^rd place

547^th place

akcchf.org

«AKC Canine Health Foundation». Akcchf.org. Consultado em 7 de junho de 2018

atsjournals.org

Raghu, Ganesh; Rochwerg, Bram; Zhang, Yuan; Garcia, Carlos A. Cuello; Azuma, Arata; Behr, Juergen; Brozek, Jan L.; Collard, Harold R.; Cunningham, William (15 de julho de 2015). «An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline». American Journal of Respiratory and Critical Care Medicine (em inglês) (2): e3–e19. ISSN 1073-449X. doi:10.1164/rccm.201506-1063ST
Raghu, Ganesh; Collard, Harold R.; Egan, Jim J.; Martinez, Fernando J.; Behr, Juergen; Brown, Kevin K.; Colby, Thomas V.; Cordier, Jean-François; Flaherty, Kevin R. (15 de março de 2011). «An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management». American Journal of Respiratory and Critical Care Medicine (em inglês) (6): 788–824. ISSN 1073-449X. doi:10.1164/rccm.2009-040GL

biomedcentral.com

fibrogenesis.biomedcentral.com

Todd, Nevins W; Luzina, Irina G; Atamas, Sergei P (dezembro de 2012). «Molecular and cellular mechanisms of pulmonary fibrosis». Fibrogenesis & Tissue Repair (em inglês) (1). ISSN 1755-1536. PMID 22824096. doi:10.1186/1755-1536-5-11

bmj.com

thorax.bmj.com

Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, et al. (2013). «Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis». Thorax. 68 (5): 436–441. PMID 23321605. doi:10.1136/thoraxjnl-2012-201786

books.google.com

Ferri FF (2017). Ferri's Clinical Advisor 2018 E-Book: 5 Books in 1 (em inglês). [S.l.]: Elsevier Health Sciences. p. 691. ISBN 9780323529570

coalitionforpf.org

«Active Clinical Trials and Investigational Research in IPF». Consultado em 4 de setembro de 2014. Cópia arquivada em 4 de setembro de 2014

doi.org

dx.doi.org

Raghu, Ganesh; Rochwerg, Bram; Zhang, Yuan; Garcia, Carlos A. Cuello; Azuma, Arata; Behr, Juergen; Brozek, Jan L.; Collard, Harold R.; Cunningham, William (15 de julho de 2015). «An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline». American Journal of Respiratory and Critical Care Medicine (em inglês) (2): e3–e19. ISSN 1073-449X. doi:10.1164/rccm.201506-1063ST
Raghu, Ganesh; Collard, Harold R.; Egan, Jim J.; Martinez, Fernando J.; Behr, Juergen; Brown, Kevin K.; Colby, Thomas V.; Cordier, Jean-François; Flaherty, Kevin R. (15 de março de 2011). «An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management». American Journal of Respiratory and Critical Care Medicine (em inglês) (6): 788–824. ISSN 1073-449X. doi:10.1164/rccm.2009-040GL
Todd, Nevins W; Luzina, Irina G; Atamas, Sergei P (dezembro de 2012). «Molecular and cellular mechanisms of pulmonary fibrosis». Fibrogenesis & Tissue Repair (em inglês) (1). ISSN 1755-1536. PMID 22824096. doi:10.1186/1755-1536-5-11
Meltzer EB, Noble PW (2008). «Idiopathic pulmonary fibrosis». Orphanet Journal of Rare Diseases. 3 (1). 8 páginas. PMC 2330030. PMID 18366757. doi:10.1186/1750-1172-3-8
Raghu, Ganesh; Remy-Jardin, Martine; Richeldi, Luca; Thomson, Carey C.; Inoue, Yoshikazu; Johkoh, Takeshi; Kreuter, Michael; Lynch, David A.; Maher, Toby M.; Martinez, Fernando J.; Molina-Molina, Maria; Myers, Jeffrey L.; Nicholson, Andrew G.; Ryerson, Christopher J.; Strek, Mary E. (1 de maio de 2022). «Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline». American Journal of Respiratory and Critical Care Medicine. 205 (9): e18–e47. ISSN 1073-449X. PMC 9851481. PMID 35486072. doi:10.1164/rccm.202202-0399ST
Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. (setembro de 2013). «An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias». American Journal of Respiratory and Critical Care Medicine. 188 (6): 733–48. PMC 5803655. PMID 24032382. doi:10.1164/rccm.201308-1483ST
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, et al. (2007). «Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia». American Journal of Respiratory and Critical Care Medicine. 168 (5): 543–548. CiteSeerX 10.1.1.320.6411. PMID 12773329. doi:10.1164/rccm.200209-1112OC
Raghu G, Weycker D, Edesberg J, Bradford WZ, Oster G (2006). «Incidence and prevalence of idiopathic pulmonary fibrosis». American Journal of Respiratory and Critical Care Medicine. 174 (7): 810–816. PMID 16809633. doi:10.1164/rccm.200602-163oc
Cottin V, Cordier JF (2012). «Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis». European Respiratory Journal. 40 (3): 519–521. PMID 22941541. doi:10.1183/09031936.00001612
Baughman RP, Shipley RT, Loudon RG, Lower EE (1991). «Crackles in interstitial lung disease. Comparison of sarcoidosis and fibrosing alveolitis». Chest. 100 (1): 96–101. PMID 2060395. doi:10.1378/chest.100.1.96
Olson AL, Swigris JJ (Mar 2012). «Idiopathic pulmonary fibrosis: diagnosis and epidemiology». Clinics in Chest Medicine. 33 (1): 41–50. PMID 22365244. doi:10.1016/j.ccm.2011.12.001
Williams, KJ (março de 2014). «Gammaherpesviruses and Pulmonary Fibrosis: Evidence From Humans, Horses, and Rodents». Veterinary Pathology. 51 (2): 372–384. PMID 24569614. doi:10.1177/0300985814521838
García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, Navarro C, Pérez-Padilla R, Vargas MH, et al. (dezembro de 2011). «Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis». Respiratory Medicine. 105 (12): 1902–7. PMID 21917441. doi:10.1016/j.rmed.2011.08.022
Harari S, Caminati A (2010). «IPF: new insight on pathogenesis and treatment». Allergy. 65 (5): 537–553. PMID 20121758. doi:10.1111/j.1398-9995.2009.02305.x
Justice JN, Nambiar AM, Tchkonia T, Kirkland JL (2019). «Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study». EBioMedicine. 40: 554–563. PMC 6412088. PMID 30616998. doi:10.1016/j.ebiom.2018.12.052
Palmer AK, Gustafson B, Kirkland JL, Smith U (2019). «Cellular senescence: at the nexus between ageing and diabetes». Diabetologia. 62 (10): 1835–1841. PMC 6731336. PMID 31451866. doi:10.1007/s00125-019-4934-x
Kirkland JL, Tchkonia T (2020). «Senolytic Drugs: From Discovery to Translation». Journal of Internal Medicine. 288 (5): 518–536. PMC 7405395. PMID 32686219. doi:10.1111/joim.13141
Loomis-King H, Flaherty KR, Moore BB (junho de 2013). «Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis». Current Opinion in Pharmacology. 13 (3): 377–385. PMC 3686907. PMID 23602652. doi:10.1016/j.coph.2013.03.015
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. (setembro de 2018). «Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline». American Journal of Respiratory and Critical Care Medicine. 198 (5): e44–e68. PMID 30168753. doi:10.1164/rccm.201807-1255ST
Maher TM, Wells AU, Laurent GJ (novembro de 2007). «Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?». The European Respiratory Journal. 30 (5): 835–839. PMID 17978154. doi:10.1183/09031936.00069307
Pardo A, Selman M (2002). «Idiopathic pulmonary fibrosis: new insights in its pathogenesis». The International Journal of Biochemistry & Cell Biology. 34 (12): 1534–1538. PMID 12379275. doi:10.1016/s1357-2725(02)00091-2
Selman M, King TE, Pardo A (2001). «Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy». Annals of Internal Medicine. 134 (2): 136–151. PMID 11177318. doi:10.7326/0003-4819-134-2-200101160-00015
Mathai S, et al. (2014). «Genetic susceptibility and pulmonary fibrosis». Current Opinion in Pulmonary Medicine. 20 (5): 429–435. PMC 4337021. PMID 25022318. doi:10.1097/MCP.0000000000000074
Kropski JA, Mitchell DB, Markin C, et al. (6 de fevereiro de 2014). «A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia». Chest. 146 (1): e1–7. PMC 4077414. PMID 24504062. doi:10.1378/chest.13-2224
Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, et al. (2004). «Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?». American Journal of Respiratory and Critical Care Medicine. 170 (8): 904–910. PMID 15256390. doi:10.1164/rccm.200402-147OC
Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, et al. (2007). «Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?». American Journal of Respiratory and Critical Care Medicine. 175 (10): 1054–1060. PMC 1899268. PMID 17255566. doi:10.1164/rccm.200606-833OC
Ohshimo S, Bonella F, Cui A, Beume M, Kohno N, Guzman J, Costabel U (2009). «Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis». American Journal of Respiratory and Critical Care Medicine. 179 (11): 1043–1047. PMID 19246718. doi:10.1164/rccm.200808-1313oc
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, et al. (2005). «Interpretative strategies for lung function tests». European Respiratory Journal. 26 (5): 948–968. PMID 16264058. doi:10.1183/09031936.05.00035205
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, et al. (2011). «Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials». The Lancet. 377 (9779): 1760–1769. PMID 21571362. doi:10.1016/S0140-6736(11)60405-4
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK (junho de 2005). «The clinical course of patients with idiopathic pulmonary fibrosis». Annals of Internal Medicine. 142 (12 Pt 1): 963–7. PMID 15968010. doi:10.7326/0003-4819-142-12_part_1-200506210-00005
King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. (maio de 2014). «A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 370 (22): 2083–92. PMID 24836312. doi:10.1056/NEJMoa1402582
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. (maio de 2014). «Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 370 (22): 2071–82. PMID 24836310. doi:10.1056/NEJMoa1402584. hdl:11365/974374
Lee JS, McLaughlin S, Collard HR (2011). «Comprehensive care of the patient with idiopathic pulmonary fibrosis». Current Opinion in Pulmonary Medicine. 17 (5): 348–354. PMID 21760508. doi:10.1097/mcp.0b013e328349721b
Morrison DA, Stovall JR (1992). «Increased exercise capacity in hypoxemic patients after long-term oxygen therapy». Chest. 102 (2): 542–550. PMID 1643945. doi:10.1378/chest.102.2.542
Spagnolo P, Tonelli R, Cocconcelli E, Stefani A, Richeldi L (2012). «Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges». Multidisciplinary Respiratory Medicine. 7 (1): 42. PMC 3537555. PMID 23146172. doi:10.1186/2049-6958-7-42
Lee JS, McLaughlin S, Collard HR (setembro de 2011). «Comprehensive care of the patient with idiopathic pulmonary fibrosis». Current Opinion in Pulmonary Medicine. 17 (5): 348–54. PMID 21760508. doi:10.1097/mcp.0b013e328349721b
Kenn K, Gloeckl R, Behr J (2013). «Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis—a review». Respiration; International Review of Thoracic Diseases. 86 (2): 89–99. PMID 23942353. doi:10.1159/000354112
King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. (julho de 2009). «Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial». Lancet. 374 (9685): 222–8. PMID 19570573. doi:10.1016/S0140-6736(09)60551-1. hdl:1942/31878
King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. (julho de 2011). «BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis» (PDF). American Journal of Respiratory and Critical Care Medicine. 184 (1): 92–9. PMID 21474646. doi:10.1164/rccm.201011-1874OC
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. (maio de 2013). «Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial». Annals of Internal Medicine. 158 (9): 641–9. PMID 23648946. doi:10.7326/0003-4819-158-9-201305070-00003
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, et al. (julho de 2012). «A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis». American Journal of Respiratory and Critical Care Medicine. 186 (1): 88–95. PMC 3400994. PMID 22561965. doi:10.1164/rccm.201202-0314OC
Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L (2010). «Non-steroid agents for idiopathic pulmonary fibrosis». Cochrane Database of Systematic Reviews (9): CD003134. PMID 20824834. doi:10.1002/14651858.CD003134.pub2. hdl:11380/680648
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al. (2005). «High-dose acetylcysteine in idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 353 (21): 2229–2242. PMID 16306520. doi:10.1056/NEJMoa042976. hdl:2066/47718
Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ (maio de 2012). «Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis». New England Journal of Medicine. 366 (21): 1968–77. PMC 3422642. PMID 22607134. doi:10.1056/NEJMoa1113354
The Idiopathic Pulmonary Fibrosis Clinical Research Network. (2014). «Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis». New England Journal of Medicine. 370 (22): 2093–2102. PMC 4116664. PMID 24836309. doi:10.1056/nejmoa1401739
Russo MJ, Iribarne A, Hong KN, Davies RR, Xydas S, Takayama H, Ibrahimiye A, Gelijns AC, Bacchetta MD, D'Ovidio F, Arcasoy S, Sonett JR (2010). «High lung allocation score is associated with increased morbidity and mortality following transplantation». Chest. 137 (3): 651–657. PMC 2832864. PMID 19820072. doi:10.1378/chest.09-0319
George TJ, Arnaoutakis GJ, Shah AS (2007). «Lung transplantation for idiopathic pulmonary fibrosis». The Annals of Thoracic Surgery. 84 (4): 1121–1128. PMID 17888957. doi:10.1016/j.athoracsur.2007.04.096
Mason DP, Brizzio ME, Alster JM, McNeill AM, Murthy SC, Budev MM, Mehta AC, Minai OA, et al. (2011). «Lung transplant in idiopathic pulmonary fibrosis». Archives of Surgery. 146 (10): 1204–1209. PMID 22006881. doi:10.1001/archsurg.2011.239
Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell G (2009). «Lung transplantation in pulmonary fibrosis challenging early outcomes counter balanced by surprisingly good outcomes beyond 15 years». Transplantation Proceedings. 41 (1): 289–291. PMID 19249537. doi:10.1016/j.transproceed.2008.10.042
Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR (2011). «Depression and functional status are strongly associated with dyspnea in interstitial lung disease» (PDF). Chest. 139 (3): 609–616. PMID 20688924. doi:10.1378/chest.10-0608. Cópia arquivada (PDF) em 1 de agosto de 2020
Allen S, Raut S, Woollard J, Vassallo M (2005). «Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis». Palliative Medicine. 19 (2): 128–130. PMID 15810751. doi:10.1191/0269216305pm998oa
JafariNezhad A, YektaKooshali MH (16 de agosto de 2018). Roviello G, ed. «Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis». PLOS ONE. 13 (8): e0202360. Bibcode:2018PLoSO..1302360J. PMC 6095562. PMID 30114238. doi:10.1371/journal.pone.0202360
Agarwal R, Jindal SK (2008). «Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review». European Journal of Internal Medicine. 19 (4): 227–235. PMID 18471669. doi:10.1016/j.ejim.2007.04.024
Stern JB, Mal H, Groussard O, Brugière O, Marceau A, Jebrak G, Fournier M (2001). «Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure». Chest. 120 (1): 213–219. PMID 11451841. doi:10.1378/chest.120.1.213
Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP (1998). «Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis» (PDF). American Journal of Respiratory and Critical Care Medicine. 157 (1): 199–203. PMID 9445300. doi:10.1164/ajrccm.157.1.9704130. Cópia arquivada (PDF) em 27 de fevereiro de 2019
Kim DS, Collard HR, King TE (junho de 2006). «Classification and natural history of the idiopathic interstitial pneumonias». Proceedings of the American Thoracic Society. 3 (4): 285–92. PMC 2658683. PMID 16738191. doi:10.1513/pats.200601-005TK
Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR (2012). «A multidimensional index and staging system for idiopathic pulmonary fibrosis». Annals of Internal Medicine. 156 (10): 684–691. CiteSeerX 10.1.1.691.4472. PMID 22586007. doi:10.7326/0003-4819-156-10-201205150-00004
Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, et al. (2014). «Predicting Survival Across Chronic Interstitial Lung Disease: The ILD-GAP Model». Chest. 145 (4): 723–728. PMID 24114524. doi:10.1378/chest.13-1474
King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW (abril de 2014). «All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials». American Journal of Respiratory and Critical Care Medicine. 189 (7): 825–31. PMID 24476390. doi:10.1164/rccm.201311-1951OC. hdl:2318/156709
Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, et al. (2013). «Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis». JAMA. 309 (21): 2232–2239. PMC 4545271. PMID 23695349. doi:10.1001/jama.2013.5827
Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, et al. (2013). «Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis». Thorax. 68 (5): 436–441. PMID 23321605. doi:10.1136/thoraxjnl-2012-201786
Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ (2006). «Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK». Thorax. 61 (11): 980–985. PMC 2121155. PMID 16844727. doi:10.1136/thx.2006.062836
Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB (2011). «The rising incidence of idiopathic pulmonary fibrosis in the U.K». Thorax. 66 (6): 462–467. PMID 21525528. doi:10.1136/thx.2010.148031
Hyldgaard C, Hilberg O, Muller A, Bendstrup E (2014). «A cohort study of interstitial lung diseases in central Denmark». Respiratory Medicine. 108 (5): 793–799. PMID 24636811. doi:10.1016/j.rmed.2013.09.002
Williams K, Malarkey D, Cohn L, Patrick D, Dye J, Toews G (2004). «Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect». Chest. 125 (6): 2278–2288. PMID 15189952. doi:10.1378/chest.125.6.2278
Liu M, Ren D, Wu D, Zheng J, Tu W (2015). «Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment». Current Stem Cell Research & Therapy. 10 (6): 466–76. PMID 25986617. doi:10.2174/1574888X10666150519092639
Onishchenko D, Marlowe RJ, Ngufor, Faust LJ, Limper AH, Hunninghake GM, Martinez FJ, Chattopadhyay I (2022). «Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.». Nature Medicine. 28 (10): 2107–2116. PMID 36175678. doi:10.1038/s41591-022-02010-y

doi.org

Taiki Furukawa et al. A comprehensible machine learning tool to differentially diagnose idiopathic pulmonary fibrosis from other chronic interstitial lung diseases. Respirology, 27(9) pp.739-746. Publicado em: 13 de junho 2022 https://doi.org/10.1111/resp.14310

europa.eu

ema.europa.eu

«Ofev | European Medicines Agency». www.ema.europa.eu. 17 de setembro de 2018. Consultado em 7 de janeiro de 2019

epp.eurostat.ec.europa.eu

«Eurostat News Release. European demography. 110/2010. 27 July 2010» (PDF). Epp.eurostat.ec.europa.eu. Consultado em 7 de junho de 2018

fda.gov

accessdata.fda.gov

«FDA Approval Package for Nintedanib» (PDF). www.accessdata.fda.gov. Consultado em 7 de janeiro de 2019

groovygecko.net

dl.groovygecko.net

«BIBF 1120 Fact Sheet» (PDF). Dl.groovygecko.net. Consultado em 8 de abril de 2014. Cópia arquivada (PDF) em 3 de março de 2016

handle.net

hdl.handle.net

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. (maio de 2014). «Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 370 (22): 2071–82. PMID 24836310. doi:10.1056/NEJMoa1402584. hdl:11365/974374
King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. (julho de 2009). «Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial». Lancet. 374 (9685): 222–8. PMID 19570573. doi:10.1016/S0140-6736(09)60551-1. hdl:1942/31878
Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L (2010). «Non-steroid agents for idiopathic pulmonary fibrosis». Cochrane Database of Systematic Reviews (9): CD003134. PMID 20824834. doi:10.1002/14651858.CD003134.pub2. hdl:11380/680648
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al. (2005). «High-dose acetylcysteine in idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 353 (21): 2229–2242. PMID 16306520. doi:10.1056/NEJMoa042976. hdl:2066/47718
King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW (abril de 2014). «All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials». American Journal of Respiratory and Critical Care Medicine. 189 (7): 825–31. PMID 24476390. doi:10.1164/rccm.201311-1951OC. hdl:2318/156709

harvard.edu

ui.adsabs.harvard.edu

JafariNezhad A, YektaKooshali MH (16 de agosto de 2018). Roviello G, ed. «Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis». PLOS ONE. 13 (8): e0202360. Bibcode:2018PLoSO..1302360J. PMC 6095562. PMID 30114238. doi:10.1371/journal.pone.0202360

nih.gov

ncbi.nlm.nih.gov

Todd, Nevins W; Luzina, Irina G; Atamas, Sergei P (dezembro de 2012). «Molecular and cellular mechanisms of pulmonary fibrosis». Fibrogenesis & Tissue Repair (em inglês) (1). ISSN 1755-1536. PMID 22824096. doi:10.1186/1755-1536-5-11
Meltzer EB, Noble PW (2008). «Idiopathic pulmonary fibrosis». Orphanet Journal of Rare Diseases. 3 (1). 8 páginas. PMC 2330030. PMID 18366757. doi:10.1186/1750-1172-3-8
Raghu, Ganesh; Remy-Jardin, Martine; Richeldi, Luca; Thomson, Carey C.; Inoue, Yoshikazu; Johkoh, Takeshi; Kreuter, Michael; Lynch, David A.; Maher, Toby M.; Martinez, Fernando J.; Molina-Molina, Maria; Myers, Jeffrey L.; Nicholson, Andrew G.; Ryerson, Christopher J.; Strek, Mary E. (1 de maio de 2022). «Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline». American Journal of Respiratory and Critical Care Medicine. 205 (9): e18–e47. ISSN 1073-449X. PMC 9851481. PMID 35486072. doi:10.1164/rccm.202202-0399ST
Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. (setembro de 2013). «An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias». American Journal of Respiratory and Critical Care Medicine. 188 (6): 733–48. PMC 5803655. PMID 24032382. doi:10.1164/rccm.201308-1483ST
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, et al. (2007). «Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia». American Journal of Respiratory and Critical Care Medicine. 168 (5): 543–548. CiteSeerX 10.1.1.320.6411. PMID 12773329. doi:10.1164/rccm.200209-1112OC
Raghu G, Weycker D, Edesberg J, Bradford WZ, Oster G (2006). «Incidence and prevalence of idiopathic pulmonary fibrosis». American Journal of Respiratory and Critical Care Medicine. 174 (7): 810–816. PMID 16809633. doi:10.1164/rccm.200602-163oc
Cottin V, Cordier JF (2012). «Velcro crackles: the key for early diagnosis of idiopathic pulmonary fibrosis». European Respiratory Journal. 40 (3): 519–521. PMID 22941541. doi:10.1183/09031936.00001612
Baughman RP, Shipley RT, Loudon RG, Lower EE (1991). «Crackles in interstitial lung disease. Comparison of sarcoidosis and fibrosing alveolitis». Chest. 100 (1): 96–101. PMID 2060395. doi:10.1378/chest.100.1.96
Olson AL, Swigris JJ (Mar 2012). «Idiopathic pulmonary fibrosis: diagnosis and epidemiology». Clinics in Chest Medicine. 33 (1): 41–50. PMID 22365244. doi:10.1016/j.ccm.2011.12.001
Williams, KJ (março de 2014). «Gammaherpesviruses and Pulmonary Fibrosis: Evidence From Humans, Horses, and Rodents». Veterinary Pathology. 51 (2): 372–384. PMID 24569614. doi:10.1177/0300985814521838
García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, Navarro C, Pérez-Padilla R, Vargas MH, et al. (dezembro de 2011). «Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis». Respiratory Medicine. 105 (12): 1902–7. PMID 21917441. doi:10.1016/j.rmed.2011.08.022
Harari S, Caminati A (2010). «IPF: new insight on pathogenesis and treatment». Allergy. 65 (5): 537–553. PMID 20121758. doi:10.1111/j.1398-9995.2009.02305.x
Justice JN, Nambiar AM, Tchkonia T, Kirkland JL (2019). «Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study». EBioMedicine. 40: 554–563. PMC 6412088. PMID 30616998. doi:10.1016/j.ebiom.2018.12.052
Palmer AK, Gustafson B, Kirkland JL, Smith U (2019). «Cellular senescence: at the nexus between ageing and diabetes». Diabetologia. 62 (10): 1835–1841. PMC 6731336. PMID 31451866. doi:10.1007/s00125-019-4934-x
Kirkland JL, Tchkonia T (2020). «Senolytic Drugs: From Discovery to Translation». Journal of Internal Medicine. 288 (5): 518–536. PMC 7405395. PMID 32686219. doi:10.1111/joim.13141
Loomis-King H, Flaherty KR, Moore BB (junho de 2013). «Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis». Current Opinion in Pharmacology. 13 (3): 377–385. PMC 3686907. PMID 23602652. doi:10.1016/j.coph.2013.03.015
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. (setembro de 2018). «Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline». American Journal of Respiratory and Critical Care Medicine. 198 (5): e44–e68. PMID 30168753. doi:10.1164/rccm.201807-1255ST
Maher TM, Wells AU, Laurent GJ (novembro de 2007). «Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?». The European Respiratory Journal. 30 (5): 835–839. PMID 17978154. doi:10.1183/09031936.00069307
Pardo A, Selman M (2002). «Idiopathic pulmonary fibrosis: new insights in its pathogenesis». The International Journal of Biochemistry & Cell Biology. 34 (12): 1534–1538. PMID 12379275. doi:10.1016/s1357-2725(02)00091-2
Selman M, King TE, Pardo A (2001). «Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy». Annals of Internal Medicine. 134 (2): 136–151. PMID 11177318. doi:10.7326/0003-4819-134-2-200101160-00015
Mathai S, et al. (2014). «Genetic susceptibility and pulmonary fibrosis». Current Opinion in Pulmonary Medicine. 20 (5): 429–435. PMC 4337021. PMID 25022318. doi:10.1097/MCP.0000000000000074
Kropski JA, Mitchell DB, Markin C, et al. (6 de fevereiro de 2014). «A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia». Chest. 146 (1): e1–7. PMC 4077414. PMID 24504062. doi:10.1378/chest.13-2224
Flaherty KR, King TE, Raghu G, Lynch JP, Colby TV, Travis WD, Gross BH, Kazerooni EA, et al. (2004). «Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?». American Journal of Respiratory and Critical Care Medicine. 170 (8): 904–910. PMID 15256390. doi:10.1164/rccm.200402-147OC
Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, et al. (2007). «Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?». American Journal of Respiratory and Critical Care Medicine. 175 (10): 1054–1060. PMC 1899268. PMID 17255566. doi:10.1164/rccm.200606-833OC
Ohshimo S, Bonella F, Cui A, Beume M, Kohno N, Guzman J, Costabel U (2009). «Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis». American Journal of Respiratory and Critical Care Medicine. 179 (11): 1043–1047. PMID 19246718. doi:10.1164/rccm.200808-1313oc
Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, et al. (2005). «Interpretative strategies for lung function tests». European Respiratory Journal. 26 (5): 948–968. PMID 16264058. doi:10.1183/09031936.05.00035205
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, et al. (2011). «Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials». The Lancet. 377 (9779): 1760–1769. PMID 21571362. doi:10.1016/S0140-6736(11)60405-4
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE, Flaherty KR, Schwartz DA, Noble PW, Raghu G, Brown KK (junho de 2005). «The clinical course of patients with idiopathic pulmonary fibrosis». Annals of Internal Medicine. 142 (12 Pt 1): 963–7. PMID 15968010. doi:10.7326/0003-4819-142-12_part_1-200506210-00005
King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. (maio de 2014). «A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 370 (22): 2083–92. PMID 24836312. doi:10.1056/NEJMoa1402582
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. (maio de 2014). «Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 370 (22): 2071–82. PMID 24836310. doi:10.1056/NEJMoa1402584. hdl:11365/974374
Lee JS, McLaughlin S, Collard HR (2011). «Comprehensive care of the patient with idiopathic pulmonary fibrosis». Current Opinion in Pulmonary Medicine. 17 (5): 348–354. PMID 21760508. doi:10.1097/mcp.0b013e328349721b
Morrison DA, Stovall JR (1992). «Increased exercise capacity in hypoxemic patients after long-term oxygen therapy». Chest. 102 (2): 542–550. PMID 1643945. doi:10.1378/chest.102.2.542
Spagnolo P, Tonelli R, Cocconcelli E, Stefani A, Richeldi L (2012). «Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges». Multidisciplinary Respiratory Medicine. 7 (1): 42. PMC 3537555. PMID 23146172. doi:10.1186/2049-6958-7-42
Lee JS, McLaughlin S, Collard HR (setembro de 2011). «Comprehensive care of the patient with idiopathic pulmonary fibrosis». Current Opinion in Pulmonary Medicine. 17 (5): 348–54. PMID 21760508. doi:10.1097/mcp.0b013e328349721b
Kenn K, Gloeckl R, Behr J (2013). «Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis—a review». Respiration; International Review of Thoracic Diseases. 86 (2): 89–99. PMID 23942353. doi:10.1159/000354112
King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. (julho de 2009). «Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial». Lancet. 374 (9685): 222–8. PMID 19570573. doi:10.1016/S0140-6736(09)60551-1. hdl:1942/31878
King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. (julho de 2011). «BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis» (PDF). American Journal of Respiratory and Critical Care Medicine. 184 (1): 92–9. PMID 21474646. doi:10.1164/rccm.201011-1874OC
Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. (maio de 2013). «Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial». Annals of Internal Medicine. 158 (9): 641–9. PMID 23648946. doi:10.7326/0003-4819-158-9-201305070-00003
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, et al. (julho de 2012). «A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis». American Journal of Respiratory and Critical Care Medicine. 186 (1): 88–95. PMC 3400994. PMID 22561965. doi:10.1164/rccm.201202-0314OC
Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters EH, D'Amico R, Richeldi L (2010). «Non-steroid agents for idiopathic pulmonary fibrosis». Cochrane Database of Systematic Reviews (9): CD003134. PMID 20824834. doi:10.1002/14651858.CD003134.pub2. hdl:11380/680648
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al. (2005). «High-dose acetylcysteine in idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 353 (21): 2229–2242. PMID 16306520. doi:10.1056/NEJMoa042976. hdl:2066/47718
Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ (maio de 2012). «Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis». New England Journal of Medicine. 366 (21): 1968–77. PMC 3422642. PMID 22607134. doi:10.1056/NEJMoa1113354
The Idiopathic Pulmonary Fibrosis Clinical Research Network. (2014). «Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis». New England Journal of Medicine. 370 (22): 2093–2102. PMC 4116664. PMID 24836309. doi:10.1056/nejmoa1401739
Russo MJ, Iribarne A, Hong KN, Davies RR, Xydas S, Takayama H, Ibrahimiye A, Gelijns AC, Bacchetta MD, D'Ovidio F, Arcasoy S, Sonett JR (2010). «High lung allocation score is associated with increased morbidity and mortality following transplantation». Chest. 137 (3): 651–657. PMC 2832864. PMID 19820072. doi:10.1378/chest.09-0319
George TJ, Arnaoutakis GJ, Shah AS (2007). «Lung transplantation for idiopathic pulmonary fibrosis». The Annals of Thoracic Surgery. 84 (4): 1121–1128. PMID 17888957. doi:10.1016/j.athoracsur.2007.04.096
Mason DP, Brizzio ME, Alster JM, McNeill AM, Murthy SC, Budev MM, Mehta AC, Minai OA, et al. (2011). «Lung transplant in idiopathic pulmonary fibrosis». Archives of Surgery. 146 (10): 1204–1209. PMID 22006881. doi:10.1001/archsurg.2011.239
Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, Snell G (2009). «Lung transplantation in pulmonary fibrosis challenging early outcomes counter balanced by surprisingly good outcomes beyond 15 years». Transplantation Proceedings. 41 (1): 289–291. PMID 19249537. doi:10.1016/j.transproceed.2008.10.042
Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR (2011). «Depression and functional status are strongly associated with dyspnea in interstitial lung disease» (PDF). Chest. 139 (3): 609–616. PMID 20688924. doi:10.1378/chest.10-0608. Cópia arquivada (PDF) em 1 de agosto de 2020
Allen S, Raut S, Woollard J, Vassallo M (2005). «Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis». Palliative Medicine. 19 (2): 128–130. PMID 15810751. doi:10.1191/0269216305pm998oa
JafariNezhad A, YektaKooshali MH (16 de agosto de 2018). Roviello G, ed. «Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis». PLOS ONE. 13 (8): e0202360. Bibcode:2018PLoSO..1302360J. PMC 6095562. PMID 30114238. doi:10.1371/journal.pone.0202360
Agarwal R, Jindal SK (2008). «Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review». European Journal of Internal Medicine. 19 (4): 227–235. PMID 18471669. doi:10.1016/j.ejim.2007.04.024
Stern JB, Mal H, Groussard O, Brugière O, Marceau A, Jebrak G, Fournier M (2001). «Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure». Chest. 120 (1): 213–219. PMID 11451841. doi:10.1378/chest.120.1.213
Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP (1998). «Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis» (PDF). American Journal of Respiratory and Critical Care Medicine. 157 (1): 199–203. PMID 9445300. doi:10.1164/ajrccm.157.1.9704130. Cópia arquivada (PDF) em 27 de fevereiro de 2019
Kim DS, Collard HR, King TE (junho de 2006). «Classification and natural history of the idiopathic interstitial pneumonias». Proceedings of the American Thoracic Society. 3 (4): 285–92. PMC 2658683. PMID 16738191. doi:10.1513/pats.200601-005TK
Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR (2012). «A multidimensional index and staging system for idiopathic pulmonary fibrosis». Annals of Internal Medicine. 156 (10): 684–691. CiteSeerX 10.1.1.691.4472. PMID 22586007. doi:10.7326/0003-4819-156-10-201205150-00004
Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, et al. (2014). «Predicting Survival Across Chronic Interstitial Lung Disease: The ILD-GAP Model». Chest. 145 (4): 723–728. PMID 24114524. doi:10.1378/chest.13-1474
King TE, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW (abril de 2014). «All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials». American Journal of Respiratory and Critical Care Medicine. 189 (7): 825–31. PMID 24476390. doi:10.1164/rccm.201311-1951OC. hdl:2318/156709
Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, et al. (2013). «Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis». JAMA. 309 (21): 2232–2239. PMC 4545271. PMID 23695349. doi:10.1001/jama.2013.5827
Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, et al. (2013). «Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis». Thorax. 68 (5): 436–441. PMID 23321605. doi:10.1136/thoraxjnl-2012-201786
Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ (2006). «Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK». Thorax. 61 (11): 980–985. PMC 2121155. PMID 16844727. doi:10.1136/thx.2006.062836
Navaratnam V, Fleming KM, West J, Smith CJ, Jenkins RG, Fogarty A, Hubbard RB (2011). «The rising incidence of idiopathic pulmonary fibrosis in the U.K». Thorax. 66 (6): 462–467. PMID 21525528. doi:10.1136/thx.2010.148031
Hyldgaard C, Hilberg O, Muller A, Bendstrup E (2014). «A cohort study of interstitial lung diseases in central Denmark». Respiratory Medicine. 108 (5): 793–799. PMID 24636811. doi:10.1016/j.rmed.2013.09.002
Williams K, Malarkey D, Cohn L, Patrick D, Dye J, Toews G (2004). «Identification of spontaneous feline idiopathic pulmonary fibrosis: morphology and ultrastructural evidence for a type II pneumocyte defect». Chest. 125 (6): 2278–2288. PMID 15189952. doi:10.1378/chest.125.6.2278
Webb JA, Armstrong J (2002). «Chronic idiopathic pulmonary fibrosis in a West Highland white terrier». The Canadian Veterinary Journal. 43 (9): 703–705. PMC 339552. PMID 12240528
Liu M, Ren D, Wu D, Zheng J, Tu W (2015). «Stem Cell and Idiopathic Pulmonary Fibrosis: Mechanisms and Treatment». Current Stem Cell Research & Therapy. 10 (6): 466–76. PMID 25986617. doi:10.2174/1574888X10666150519092639
Onishchenko D, Marlowe RJ, Ngufor, Faust LJ, Limper AH, Hunninghake GM, Martinez FJ, Chattopadhyay I (2022). «Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.». Nature Medicine. 28 (10): 2107–2116. PMID 36175678. doi:10.1038/s41591-022-02010-y

nhlbi.nih.gov

«Idiopathic Pulmonary Fibrosis». NHLBI. Consultado em 21 de janeiro de 2018
«Idiopathic Pulmonary Fibrosis». NHLBI, NIH. Consultado em 5 de dezembro de 2020

nih.gov

«Commonly used three-drug regimen for idiopathic pulmonary fibrosis found harmful». NIH. 21 de outubro de 2011. Consultado em 11 de abril de 2013

omim.org

«OMIM Entry – # 178500 – PULMONARY FIBROSIS, IDIOPATHIC; IPF». Omim.org. Consultado em 7 de junho de 2018

psu.edu

citeseerx.ist.psu.edu

Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, et al. (2007). «Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia». American Journal of Respiratory and Critical Care Medicine. 168 (5): 543–548. CiteSeerX 10.1.1.320.6411. PMID 12773329. doi:10.1164/rccm.200209-1112OC
Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR (2012). «A multidimensional index and staging system for idiopathic pulmonary fibrosis». Annals of Internal Medicine. 156 (10): 684–691. CiteSeerX 10.1.1.691.4472. PMID 22586007. doi:10.7326/0003-4819-156-10-201205150-00004

pulmonaryfibrosisnews.com

«Research Demonstrates Reversal Of Pulmonary Fibrosis With miRagen Therapeutics Synthetic microRNA-29 Mimic (promiR-29)». Pulmonaryfibrosisnews.com. 23 de setembro de 2014. Consultado em 8 de junho de 2018

sciencedaily.com

«Stem cell therapy for lung fibrosis conditions». Sciencedaily.com. Consultado em 8 de junho de 2018

semanticscholar.org

pdfs.semanticscholar.org

King TE, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. (julho de 2011). «BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis» (PDF). American Journal of Respiratory and Critical Care Medicine. 184 (1): 92–9. PMID 21474646. doi:10.1164/rccm.201011-1874OC
Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR (2011). «Depression and functional status are strongly associated with dyspnea in interstitial lung disease» (PDF). Chest. 139 (3): 609–616. PMID 20688924. doi:10.1378/chest.10-0608. Cópia arquivada (PDF) em 1 de agosto de 2020
Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP (1998). «Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis» (PDF). American Journal of Respiratory and Critical Care Medicine. 157 (1): 199–203. PMID 9445300. doi:10.1164/ajrccm.157.1.9704130. Cópia arquivada (PDF) em 27 de fevereiro de 2019

unisi.it

usiena-air.unisi.it

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. (maio de 2014). «Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 370 (22): 2071–82. PMID 24836310. doi:10.1056/NEJMoa1402584. hdl:11365/974374

uq.edu.au

espace.library.uq.edu.au

King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. (maio de 2014). «A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 370 (22): 2083–92. PMID 24836312. doi:10.1056/NEJMoa1402582

uva.nl

pure.uva.nl

Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, et al. (2005). «High-dose acetylcysteine in idiopathic pulmonary fibrosis» (PDF). New England Journal of Medicine. 353 (21): 2229–2242. PMID 16306520. doi:10.1056/NEJMoa042976. hdl:2066/47718

web.archive.org

«BIBF 1120 Fact Sheet» (PDF). Dl.groovygecko.net. Consultado em 8 de abril de 2014. Cópia arquivada (PDF) em 3 de março de 2016
Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, Pantilat SZ, Landefeld CS, Collard HR (2011). «Depression and functional status are strongly associated with dyspnea in interstitial lung disease» (PDF). Chest. 139 (3): 609–616. PMID 20688924. doi:10.1378/chest.10-0608. Cópia arquivada (PDF) em 1 de agosto de 2020
Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP (1998). «Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis» (PDF). American Journal of Respiratory and Critical Care Medicine. 157 (1): 199–203. PMID 9445300. doi:10.1164/ajrccm.157.1.9704130. Cópia arquivada (PDF) em 27 de fevereiro de 2019
«Active Clinical Trials and Investigational Research in IPF». Consultado em 4 de setembro de 2014. Cópia arquivada em 4 de setembro de 2014

worldcat.org

Raghu, Ganesh; Rochwerg, Bram; Zhang, Yuan; Garcia, Carlos A. Cuello; Azuma, Arata; Behr, Juergen; Brozek, Jan L.; Collard, Harold R.; Cunningham, William (15 de julho de 2015). «An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline». American Journal of Respiratory and Critical Care Medicine (em inglês) (2): e3–e19. ISSN 1073-449X. doi:10.1164/rccm.201506-1063ST
Raghu, Ganesh; Collard, Harold R.; Egan, Jim J.; Martinez, Fernando J.; Behr, Juergen; Brown, Kevin K.; Colby, Thomas V.; Cordier, Jean-François; Flaherty, Kevin R. (15 de março de 2011). «An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management». American Journal of Respiratory and Critical Care Medicine (em inglês) (6): 788–824. ISSN 1073-449X. doi:10.1164/rccm.2009-040GL
Todd, Nevins W; Luzina, Irina G; Atamas, Sergei P (dezembro de 2012). «Molecular and cellular mechanisms of pulmonary fibrosis». Fibrogenesis & Tissue Repair (em inglês) (1). ISSN 1755-1536. PMID 22824096. doi:10.1186/1755-1536-5-11
Raghu, Ganesh; Remy-Jardin, Martine; Richeldi, Luca; Thomson, Carey C.; Inoue, Yoshikazu; Johkoh, Takeshi; Kreuter, Michael; Lynch, David A.; Maher, Toby M.; Martinez, Fernando J.; Molina-Molina, Maria; Myers, Jeffrey L.; Nicholson, Andrew G.; Ryerson, Christopher J.; Strek, Mary E. (1 de maio de 2022). «Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline». American Journal of Respiratory and Critical Care Medicine. 205 (9): e18–e47. ISSN 1073-449X. PMC 9851481. PMID 35486072. doi:10.1164/rccm.202202-0399ST